Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer
- Resource Type
- Brief Communication
- Authors
- Burrows, Natalie; Maxwell, Patrick H.
- Source
- Nature Reviews Urology. 18(9):516-517
- Subject
- Language
- English
- ISSN
- 1759-4812
1759-4820
A new phase I clinical trial has demonstrated that belzutifan provides a route to sustained inhibition of hypoxia-inducible factor 2α in humans that is well tolerated and could be useful in the treatment of advanced clear cell kidney cancer.